MOTS-c: Benefits, Dosage, Side Effects, and How to Get It in 2026
Medically reviewed by the Rite Aid Health Team · Last updated June 16, 2026
MOTS-c is a mitochondrial-derived peptide — one of the few peptides encoded not in the cell's nuclear DNA but in the mitochondrial genome.
It is studied for its role in regulating metabolism and insulin sensitivity, promoting fat metabolism and exercise capacity, and for its potential in metabolic health and longevity.
In research it behaves as a mitochondrial "exercise mimetic." It is one of the 12 peptides the FDA removed from its Section 503A Category 2 list in April 2026, and one of seven peptides under formal advisory review on July 23–24, 2026. New to the broader peptide category? Start with our peptide therapy guide.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
What is MOTS-c?
MOTS-c is a peptide encoded within mitochondrial DNA — the small, separate genome inside the cell's mitochondria. This makes it a mitochondrial-derived peptide, a class distinct from the synthetic and gastric-origin peptides elsewhere in this section.
It occurs naturally in the body and acts as a signaling molecule involved in cellular energy metabolism. It is not FDA-approved as a drug in the United States.
Benefits and uses
What the research has examined — most of it preclinical, with human data still emerging:
- Metabolism and insulin sensitivity. The central finding; MOTS-c regulates metabolic pathways and improves insulin sensitivity in research models.
- Fat metabolism. Studied for promoting the use of fat for energy, which underlies its interest for weight and metabolic health.
- Exercise capacity. Acts as an "exercise mimetic" in research — reproducing some of the metabolic adaptations associated with physical training.
- Longevity. Investigated in the context of metabolic aging and healthspan.
The honest framing: the metabolic findings are compelling in preclinical work, but human clinical data is still emerging and much of the evidence base is animal and cell research.
How it works
MOTS-c is produced from the mitochondrial genome and acts as a metabolic regulator. In research it influences the AMPK pathway — a central cellular energy sensor — which shifts cells toward fat oxidation and improved glucose handling.
This mechanism is why it is described as an exercise mimetic: it triggers some of the same metabolic signaling that physical exercise produces. It also translocates to the cell nucleus under metabolic stress, where it helps regulate the cell's adaptive response.
Dosage and administration
MOTS-c is administered by subcutaneous injection. There is no FDA-approved MOTS-c product and no official dosing guideline. Protocols vary and are often run in cycles. Dosing should be set by a prescribing provider.
Use the peptide dosage calculator to convert a target dose into the right volume for your vial size.
Side effects and safety
MOTS-c is generally reported to be well tolerated, with injection-site reactions the most commonly mentioned effect. Because human use is recent and the clinical data is emerging, long-term safety data does not exist.
Given its effect on glucose metabolism, anyone using MOTS-c — particularly people with diabetes or on glucose-lowering medication — should monitor blood sugar and work with a provider.
How to get MOTS-c in 2026
The regulatory status changed this year:
- For several years MOTS-c sat on the FDA's Section 503A Category 2 list, which effectively blocked compounding pharmacies from preparing it.
- On April 15, 2026 the FDA removed MOTS-c (and 11 other peptides) from that Category 2 list.
- A Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 will evaluate whether MOTS-c should be formally added to the authorized bulk-substances list compounding pharmacies can use.
Until that process completes, the cleanest legal route is a prescription filled by a licensed compounding pharmacy. Products sold online "for research use only" are not manufactured or quality-controlled for human use, and buying them carries both quality and legal risk.
Rite Aid is preparing compounded peptide consultations. Join the waitlist to claim 20% off your first MOTS-c order when consultations and ordering open.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
MOTS-c vs other metabolic and longevity peptides
MOTS-c is often considered alongside peptides used for metabolic and longevity goals. It is compared with Tesamorelin, the FDA-approved peptide for visceral fat, and grouped with Epitalon in longevity protocols.
For a broader plan, compare MOTS-c with other weight loss and anti-aging and longevity peptides.
Blood work to track MOTS-c
Because MOTS-c acts on metabolism and insulin sensitivity, a metabolic panel is the most relevant baseline:
- Comprehensive metabolic profile — glucose, liver enzymes, and kidney function; the metabolic and safety baseline for a MOTS-c cycle.
Test before you start and again at 4–6 weeks to see whether metabolic markers shift.
Baseline tests before a peptide cycle
Check safety and response markers before starting. These tests help establish a baseline for liver, kidney, glucose, hormone, and recovery tracking.
FAQ
Studied for metabolism and insulin sensitivity, fat metabolism, exercise capacity, and longevity. It acts as a mitochondrial "exercise mimetic" in research. Human data is emerging and much of the evidence is preclinical.
The FDA removed MOTS-c from the Category 2 list that restricted compounding in April 2026, and a July 2026 advisory meeting will review formal authorization. A prescription filled by a licensed compounding pharmacy is the cleanest legal route. "Research use only" products are not approved for human use.
MOTS-c is a mitochondrial-derived peptide — it is encoded in mitochondrial DNA rather than the cell's nuclear genome. It acts as a metabolic signaling molecule.
MOTS-c is given by subcutaneous injection, often in cycles. There is no FDA-approved product or official dosing. Dosing should be set by a prescribing provider.
Injection-site reactions are the most commonly mentioned. Long-term human safety data does not exist. Because it affects glucose metabolism, people with diabetes or on glucose-lowering medication should monitor blood sugar with a provider.
It is studied for fat metabolism and insulin sensitivity, which underlie its interest for metabolic health and weight. The findings are largely preclinical, with human data still emerging.